Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Non Small Cell Lung Cancer · Pancreatic Ductal Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Carolina BioOncology Institute, Huntersville, North Carolina, United States
Sarah Cannon Research Institute University of Oklahoma, Oklahoma City, Oklahoma, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Tranquility Research, Webster, Texas, United States
NEXT Oncology, Fairfax, Virginia, United States